NASDAQ:IBB iShares Biotechnology ETF (IBB) Price, Holdings, & News $210.71 +3.55 (+1.72%) As of 12:10 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHoldingsNews and TrendsOptions ChainOwnershipRatingsSEC FilingsShort Interest About iShares Biotechnology ETF (NASDAQ:IBB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get IBB alerts:Sign Up Key Stats Today's Range$207.20▼$211.6450-Day Range$185.91▼$216.9652-Week Range$138.79▼$217.12Volume682,891 shsAverage Volume1.63 million shsMarket Capitalization$10.80 billionAssets Under Management$10.52 billionDividend Yield0.16%Net Expense Ratio0.44%Aggregate RatingModerate Buy ETF Overview iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund’s investment advisor is BlackRock Fund Advisors, which is indirectly owned by BlackRock, Inc. Read More iShares Biotechnology ETF ExpensesTypeIBBHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.44%0.55%0.57%0.54%0.53%Other Expenses0.00%0.52%0.53%0.38%0.54%Total Expense0.44%0.76%0.75%0.69%0.73%Fee Waiver0.00%-0.85%-0.67%-0.41%-0.68%Net Expense0.44%0.58%0.63%0.61%0.60% Receive IBB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iShares Biotechnology ETF and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IBB ETF News Headlines5 Undervalued Oncology Stocks Wall Street Is OverlookingSeptember 18, 2026 | seekingalpha.comIBB Just Beat the S&P 500 by 22 Points in Three Months. Are You Late to the Party?September 7, 2026 | 247wallst.comThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This past May, flooding hit the same complex again, and in July Cigar Lake went down a second time, disrupting the world's largest high-grade uranium mine. Gerardo Del Real calls this the Third Convergence Event and has backed three small companies positioned in front of it.September 22 at 1:00 AM | Digest Publishing (Ad)Sector Update: Healthcare Stocks Flat to Higher Premarket WednesdaySeptember 2, 2026 | finance.yahoo.comAmid the chip bear market, healthcare is breaking out: Chart of the dayAugust 21, 2026 | msn.comModerna Rallies 8%, BioNTech Climbs 4% as the mRNA Trade Whipsaws for a Third SessionAugust 21, 2026 | 247wallst.comSee More Headlines IBB ETF - Frequently Asked Questions How have IBB shares performed this year? iShares Biotechnology ETF's stock was trading at $168.77 on January 1st, 2026. Since then, IBB stock has increased by 23.9% and is now trading at $209.12. When did iShares Biotechnology ETF's stock split? Shares of iShares Biotechnology ETF split before market open on Friday, December 1st 2017.The 3-1 split was announced on Tuesday, November 7th 2017. The newly created shares were payable to shareholders after the closing bell on Thursday, November 30th 2017. An investor that had 100 shares of stock prior to the split would have 300 shares after the split. Who are iShares Biotechnology ETF's major shareholders? Top institutional investors of iShares Biotechnology ETF include Janney Montgomery Scott LLC (1.32%), The Manufacturers Life Insurance Company (0.21%), Apella Capital LLC (0.12%) and Corient Private Wealth LP (0.11%). How do I buy shares of iShares Biotechnology ETF? Shares of IBB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of iShares Biotechnology ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that iShares Biotechnology ETF investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC). Fund Details IssueriShares Fund NameiShares Biotechnology ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:IBB Inception Date2/5/2001 Fund ManagerDiane Hsiung, Jennifer Hsui, Greg Savage, Alan Mason WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkNYSE Biotechnology Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings0 Fund Statistics Assets Under Management$10.52 billion Average Daily Volume$1.47 million Discount/Premium-0.05% Administrator, Advisor and Custodian AdministratorJ.P. Morgan Chase Bank, N.A. AdvisorBlackRock Fund Advisors CustodianJPMorgan Chase Bank, N.A. DistributorBlackRock Investments, LLC Transfer AgentJ.P. Morgan Chase Bank, N.A. TrusteeN/A Lead Market MakerLatour Trading Options OptionableOptionable Options Volume1,886 Put Options267 Call Options1,619 Short Interest10,985,379 shs Miscellaneous Outstanding Shares51,250,000Beta0.71 Creation Unit50,000 Creation Fee$614.00 10 Best Stocks to Own - Fall 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report Top 10 IBB HoldingsVertex Pharmaceuticals (NASDAQ:VRTX)Holding Weight: 7.95%Amgen (NASDAQ:AMGN)Holding Weight: 7.73%Gilead Sciences (NASDAQ:GILD)Holding Weight: 7.38%Regeneron Pharmaceuticals (NASDAQ:REGN)Holding Weight: 5.83%Moderna (NASDAQ:MRNA)Holding Weight: 3.87%argenex (NASDAQ:ARGX)Holding Weight: 3.78%Natera (NASDAQ:NTRA)Holding Weight: 3.32%Revolution Medicines (NASDAQ:RVMD)Holding Weight: 2.87%Alnylam Pharmaceuticals (NASDAQ:ALNY)Holding Weight: 2.44%Biogen (NASDAQ:BIIB)Holding Weight: 2.35%Full Holdings DetailsIBB Sector ExposureIBB Industry Exposure This page (NASDAQ:IBB) was last updated on 9/22/2026 by MarketBeat.com Staff. From Our PartnersChina's dominance in rare earth processing sparks new defense rulesOn January 1, 2027, new Pentagon rules tighten sourcing restrictions on critical minerals tied to foreign adve...The Tomorrow Investor | Sponsored$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredInside Nevada's 60 Million Ounce Gold CorridorBarrick Mining has spent decades building one of the world's great gold districts in Nevada, anchored by Fourm...Wall Street Logic | SponsoredA councilman backed AI — then 13 bullets hit his front doorThirteen bullets hit an Indianapolis councilman's front door days after he backed a data center rezoning. Acro...Stansberry Research | SponsoredElon Musk’s Hushed FCC Filing. Sept 25th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | SponsoredPass by August 7… or wait until 2027?On August 14, federal regulators cleared a national trust bank tied to the Trump family's crypto venture. W...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iShares Biotechnology ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share iShares Biotechnology ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IBB Stock Alerts